Targeting SARS-CoV-2 Variants with Nucleic Acid Therapeutic Nanoparticle Conjugates

The emergence of SARS-CoV-2 variants is cause for concern, because these may become resistant to current vaccines and antiviral drugs in development. Current drugs target viral proteins, resulting in a critical need for RNA-targeted nanomedicines. To address this, a comparative analysis of SARS-CoV-...

Descripción completa

Detalles Bibliográficos
Autores principales: Huber, Hanah F., Jaberi-Douraki, Majid, DeVader, Sarah, Aparicio-Lopez, Cesar, Nava-Chavez, Juliet, Xu, Xuan, Millagaha Gedara, Nuwan Indika, Gaudreault, Natasha N., Delong, Robert K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8539335/
https://www.ncbi.nlm.nih.gov/pubmed/34681236
http://dx.doi.org/10.3390/ph14101012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8539335/
https://www.ncbi.nlm.nih.gov/pubmed/34681236
http://dx.doi.org/10.3390/ph14101012

Ejemplares similares